In an analysis of outcomes reported in the Journal of Clinical Oncology, men who were diagnosed with lymph node-positive prostate cancer (no bone involvement) who went on to receive targeted radiation (adjuvant radiotherapy) enjoyed a survival benefit over those individuals who did not have this therapy. This finding was specifically for men with both low-volume [...]
Men with metastatic castrate resistant prostate cancer (mCRPC) have become fortunate over the last few years as there we now have a number of new drugs available which can extend our life and can also have some palliative effects. However, as we have more treatments being approved, we find that we are faced with a [...]
Intermittent hormone therapy (IHT) as opposed to continuous hormone therapy (CHT) provides a better quality of life (QoL) for men with locally advanced prostate cancer. However, there is a debate created by a few major research protocols that have been inconclusive as to the difference in achieving the ultimate goal, survival despite prostate cancer. Researchers [...]
Clinical trials for treatment of men with advanced prostate cancer often don’t include men who are considered very elderly (aged over 80 years). So, even if we know that a treatment is tolerable and effective in the average man, we can not assume that it would also be in the very elderly, especially in reference [...]
I have been informed that it is now possible for men in need of the treatment Xofigo to obtain it without having to pay any co-pays. The program that is making this possible is called Xofigo Access Services and is designed to make Xofigo available for men with a commercial medical insurance policy (not medicaid [...]